ABSTRACT
AIM: To report a case of Susac-syndrome (SS) in a 25 years old female with sudden peripheral visual field defects and hearing loss.METHODS: A 25 years old female with sudden peri-pheral visual field defects and hearing loss was reported, and the correlations between retinal findings in ultra-widefield-angiography and presented visual field defects were documented.RESULTS: Our patient presented the characteristic clinical triad of SS. Certain correlations between retinal findings in ultra-widefield-angiography and visual field defects could be shown.CONCLUSION: Ultra-widefield-angiography has been proven to be a valuable tool to detect and follow peripheral lesions of SS in clinical management.
ABSTRACT
AIM: To investigate patient assessed visual function and visual acuity after treatment with the unselective anti-VEGF inhibitor bevacizumab in diabetic macular edema after scatter laser photocoagulation due to proliferative diabetic retinopathy(PDR).METHODS: The case series of consecutive 30 eyes of 30 patients with PDR and persistent diabetic macular edema were treated with a single intravitreal dose of 1.25mg bevacizumab in 0.05mL (Avastin) in combination with scatter argon laser photocoagulation. The control group consisted of 30 eyes of 30 patients with PDR who received scatter laser photocoagulation alone. Main outcome measures were Snellen visual acuity,fundus clinical findings and patients self estimated quality of vision evaluated in scale of 0-100 percentages.RESULTS: Baseline visual acuity was mean 0.48±0.58 logMAR in the bevacizumab group and 0.61±0.78 (n.s.) in the control group. After 6 months,visual acuity hat not changed significantly to 0.33±0.41 and 0.52±0.68 in the bevacizumab and control group,respectively. Clinical examination showed only a trend to some improvement in macular edema. Subjective patient assessment of visual function on the visual analogue scale (VAS) showed an improvement from 60.2±17.5 to 76.0±15.6 (P<0.01) 6 months after the injection of bevacizumab. In the control group self-assessed visual function was mean 59.6±19.8,which did not differ from the baseline bevacizumab group (n.s.) but was high significantly (P<0.01) lower than after bevacizumab. CONCLUSION: Self-assessed visual acuity and patient satisfaction were significantly improved after intravitreal bevacizumab (Avastin) as additional therapy to scatter laser photocoagulation therapy for macular edema in PDR than after laser therapy alone. Visual acuity did not change significantly in this comparative case series over 6 months.KEYWORDS: proliferative diabetic retinopathy; visual acuity; self assessment; bevacizumab; scatter laser photocoagulation